Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Eylea

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Eylea was produced by Bayer.

Trials of Roche's new blindness candidate now underway

Trials of Roche's new blindness candidate now underway While multiple therapies exist for wet AMD - Lucentis competes in the market with Bayer's Eylea (aflibercept) as well as off-label use of Roche's cancer drug Avastin (bevacizumab) - there

Top biotech firms saw sales jump in 2014

Top biotech firms saw sales jump in 2014 Dion explains: “Regeneron's sales grew by 34% in 2014, as the company continued its commercialisation of [eye disease drug] Eylea (afilibercept) to markets outside the US, including for the treatment

The BMJ weighs in on Avastin/Lucentis debate

The BMJ weighs in on Avastin/Lucentis debate Currently, General Medical Council guidance and European drug licensing laws say that Lucentis (ranibizumab), developed by Novartis and Roche, and Bayer/Regeneron's Eylea (aflibercept) - that are both approved to treat ... ahead of Lucentis and Eylea for

Bayer's Eylea cleared for wider use in Europe

Bayer's Eylea cleared for wider use in Europe The European Commission has approved Eylea (aflibercept) for the treatment of patients with macular oedema secondary to retinal vein occlusion. ... Eylea is being co-developed by Bayer and Regeneron, with Bayer holding exclusive marketing rights to the

UK doctors call on NHS to use Avastin for wet AMD

UK doctors call on NHS to use Avastin for wet AMD Currently, GMC guidance and European drug licensing laws say that Lucentis (ranibizumab), from Novartis and Roche, and Bayer/Regeneron's Eylea(aflibercept) - that are approved to treat wet AMD - should be ... Eylea because it is around a tenth of the

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...